264 related articles for article (PubMed ID: 27590631)
41. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Jokinen E; Koivunen JP
Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
[TBL] [Abstract][Full Text] [Related]
42. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
[TBL] [Abstract][Full Text] [Related]
44. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
46. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
[TBL] [Abstract][Full Text] [Related]
47. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
[TBL] [Abstract][Full Text] [Related]
48. Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT.
Liu Y; Yang EJ; Shi C; Mou PK; Zhang B; Wu C; Lyu J; Shim JS
Int J Biol Sci; 2020; 16(11):1774-1784. PubMed ID: 32398948
[TBL] [Abstract][Full Text] [Related]
49. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
50. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
51. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
52. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
53. Bcl-xL inhibition radiosensitizes
Pesch AM; Chandler BC; Michmerhuizen AR; Carter HM; Hirsh NH; Wilder-Romans K; Liu M; Ward T; Ritter CL; Nino CA; Jungles KM; Pierce LJ; Rae JM; Speers CW
Cancer Res Commun; 2022 Jul; 2(7):679-693. PubMed ID: 36381235
[TBL] [Abstract][Full Text] [Related]
54. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
[TBL] [Abstract][Full Text] [Related]
55. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
56. SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM‑1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo.
Yin J; Li X; Zhang Z; Luo X; Wang L; Liu L
Int J Oncol; 2018 Jul; 53(1):297-306. PubMed ID: 29749435
[TBL] [Abstract][Full Text] [Related]
57. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth.
Ghosh-Choudhury N; Mandal CC; Ghosh-Choudhury N; Ghosh Choudhury G
Cell Signal; 2010 May; 22(5):749-58. PubMed ID: 20060890
[TBL] [Abstract][Full Text] [Related]
58. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
59. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
[TBL] [Abstract][Full Text] [Related]
60. AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
Khan MI; Hamid A; Rath S; Ateeq B; Khan Q; Siddiqui IA; Adhami VM; Choudhry H; Zamzami MA; Mukhtar H
Mol Cancer Ther; 2019 Feb; 18(2):356-363. PubMed ID: 30446585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
